Key Points
- Edwards Lifesciences VP Daniel Lippis sold 620 shares on May 18 at an average price of $81.14, totaling about $50,306.80. After the sale, he still held 40,411 shares worth roughly $3.28 million.
- The transaction was made under a pre-arranged Rule 10b5-1 trading plan, indicating it was planned in advance rather than tied to an immediate market move.
- The company recently reported strong quarterly results, with EPS of $0.78 and revenue of $1.65 billion, both above analyst expectations. Analysts currently rate the stock a Moderate Buy with an average price target of $95.65.
Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) VP Daniel Lippis sold 620 shares of Edwards Lifesciences stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $81.14, for a total transaction of $50,306.80. Following the completion of the sale, the vice president owned 40,411 shares of the company's stock, valued at $3,278,948.54. This trade represents a 1.51% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Edwards Lifesciences Price Performance
Shares of Edwards Lifesciences stock opened at $82.39 on Tuesday. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $87.89. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The company has a 50-day simple moving average of $81.48 and a two-hundred day simple moving average of $82.87. The stock has a market capitalization of $47.44 billion, a price-to-earnings ratio of 43.82, a price-to-earnings-growth ratio of 2.04 and a beta of 0.87.
Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business had revenue of $1.65 billion during the quarter, compared to analysts' expectations of $1.60 billion. During the same quarter in the previous year, the company earned $0.64 EPS. The business's revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current year.
Hedge Funds Weigh In On Edwards Lifesciences
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. increased its position in Edwards Lifesciences by 13.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company's stock valued at $6,706,000 after acquiring an additional 10,078 shares during the period. Atlantic Union Bankshares Corp increased its position in Edwards Lifesciences by 2,240.9% in the 3rd quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company's stock valued at $925,000 after acquiring an additional 11,384 shares during the period. Washington Trust Advisors Inc. increased its position in Edwards Lifesciences by 15.6% in the 3rd quarter. Washington Trust Advisors Inc. now owns 130,587 shares of the medical research company's stock valued at $10,156,000 after acquiring an additional 17,625 shares during the period. Bank of New York Mellon Corp increased its position in Edwards Lifesciences by 8.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company's stock valued at $1,478,425,000 after acquiring an additional 1,423,365 shares during the period. Finally, Azzad Asset Management Inc. ADV increased its position in shares of Edwards Lifesciences by 330.5% during the third quarter. Azzad Asset Management Inc. ADV now owns 21,227 shares of the medical research company's stock worth $1,651,000 after buying an additional 16,296 shares during the period. Institutional investors own 79.46% of the company's stock.
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on EW. Robert W. Baird lifted their price objective on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a "neutral" rating in a research note on Friday, April 24th. The Goldman Sachs Group reiterated a "buy" rating and issued a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Barclays reiterated an "overweight" rating and issued a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Wolfe Research upgraded shares of Edwards Lifesciences from a "peer perform" rating to an "outperform" rating and set a $92.00 target price for the company in a research report on Wednesday, April 1st. Finally, UBS Group restated a "neutral" rating and issued a $94.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of "Moderate Buy" and an average price target of $95.65.
Check Out Our Latest Report on Edwards Lifesciences
Edwards Lifesciences Company Profile
(
Get Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
